

Supplementary table 1: Risk factors for in hospital mortality from COVID-19 patients

Variable	Death Alive	HR (95%CI)	P-Value
Age (Per Year increase)¹		1.03(1.0-1.04)	≤0.0001
<50	63 376	Reference	
≥50	93 157	2.33(1.67-3.25)	≤0.0001
Gender¹			
Female	62 289	Reference	
Male	94 244	1.39(1.00-1.94)	0.046
Co-morbidities²			
No	98 462	Reference	
Yes	58 71	1.71(1.22- 2.40)	0.002
Number of co morbid conditions²			
0	98 462	Reference	
1	30 41	1.79(1.18-2.72)	0.006
>1	28 30	1.63(1.05-2.52)	0.027
Types Co-morbid conditions:-			
Hypertension only²			
No	123 500	Reference	
Yes	10 8	2.47(1.29-4.73)	0.006
Hypertension with other comorbidities²			
No	123 500	Reference	
Yes	33 33	1.75(1.18-2.59)	0.005
hypertension with diabetes²			
No	138 516	Reference	
Yes	18 17	1.56(0.94-2.57)	0.080
Diabetes only²			
No	123 499	Reference	
Yes	11 14	1.64(0.88-3.06)	0.119
Diabetes with other comorbidities²			
No	123 499	Reference	
Yes	33 34	1.61(1.08-2.39)	0.018
Symptoms at the time of presentation¹			
No	6 68	Reference	
Yes	150 465	2.39(1.05-5.44)	0.037
Severe Acute Respiratory Infection¹			
No	94 419	Reference	
Yes	62 114	1.18(0.82-1.68)	0.356
Respiratory support¹			
No	89 520	Reference	
Yes	67 13	3.95(2.84- 5.50)	≤0.0001
No treatment²			
Yes	3 85	Reference	
Yes	153 448	3.57(1.13-11.28)	0.030

Only HCQ²			
No treatment	3 85	Reference	
Yes	1 35	0.13(0.009- 2.01)	0.147
Only Azithromycin²			
No treatment	3 85	Reference	
Yes	13 224	0.72(0.18- 2.80)	
Azithromycin + HCQ²			
No treatment	3 85	Reference	
Yes	131 178	6.00(1.89- 19.07)	0.002
Azithromycin + Steroids²			
No treatment	3 85	Reference	
Yes	67 13	11.74(3.45-39.97)	≤0.0001
Azithromycin + Lopinavir–Ritonavir²			
No treatment	3 85	Reference	
Yes	7 6	5.82(1.20-28.25)	0.029
Azithromycin + Oseltamivir²			
No treatment	3 85	Reference	
Yes	119 40	14.90(4.60-48.22)	≤0.0001

1: adjusted for age (continuous), gender, comorbidities (yes/no)

2: adjusted for age (continuous), gender